ATARAX CAP 10MG 10 MG
HYDROXYZINE HYDROCHLORIDE : 10 MG · DIN 00024376 · ERFA CANADA 2012 INC
Health Canada status: CANCELLED POST MARKET
What is ATARAX CAP 10MG?
ATARAX CAP 10MG 10 MG contains HYDROXYZINE HYDROCHLORIDE : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 00024376, held by ERFA CANADA 2012 INC, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 15-Sep-2005. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ATARAX CAP 10MG used for?
Management of anxiety, tension, acute emotional problems, pruritus due to allergic conditions, and control of nausea and vomiting (excluding pregnancy). IM used for acute disturbed/alcoholic patients.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 00024376 |
|---|---|
| Brand name | ATARAX CAP 10MG |
| Generic / active ingredient | HYDROXYZINE HYDROCHLORIDE : 10 MG |
| Manufacturer | ERFA CANADA 2012 INC |
| Strength | 10 MG |
| Dosage form | CAPSULE |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N05BB01 HYDROXYZINE |
| AHFS class | 28:24.92 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 15-Sep-2005 |
| Original market date | 1956-12-31 00:00:00 |
How is it administered?
Oral: Adults 25-100 mg 3-4 times daily. IM: 25-100 mg. IM must be deep intramuscular injection only; do not inject SC, IV, or intra-arterially. Narcotic doses may need 50% reduction.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
null
How is it supplied?
Syrup: 473 mL bottles. Injection: 10 mL vials and 1 mL vials (boxes of 10). Capsules: Bottles of 100.
Contraindications
Known hypersensitivity to hydroxyzine hydrochloride or any component; early pregnancy; nausea and vomiting of pregnancy.
Warnings and precautions
Caution in patients with epilepsy. May cause drowsiness; caution against driving or operating machinery. IM route only; avoid SC, IV, or intra-arterial injection.
Is HYDROXYZINE in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by AA PHARMA INC, last seen 16 Jun 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code N05BB01 HYDROXYZINE. 5 of 29 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ATARAX | 10 MG / 5 ML | SYRUP | SEARCHLIGHT PHARMA INC | MARKETED | DIN 00024694 |
| HYDROXYZINE | 10 MG | CAPSULE | AA PHARMA INC | MARKETED | DIN 00646059 |
| HYDROXYZINE | 25 MG | CAPSULE | AA PHARMA INC | MARKETED | DIN 00646024 |
| HYDROXYZINE | 50 MG | CAPSULE | AA PHARMA INC | MARKETED | DIN 00646016 |
| HYDROXYZINE HYDROCHLORIDE INJECTION USP | 50 MG | LIQUID | SANDOZ CANADA INCORPORATED | MARKETED | DIN 00742813 |
| ATARAX CAP 25MG | 25 MG | CAPSULE | ERFA CANADA 2012 INC | CANCELLED POST MARKET | DIN 00024384 |
| ATARAX CAP 50MG | 50 MG | CAPSULE | ERFA CANADA 2012 INC | CANCELLED POST MARKET | DIN 00024392 |
| ATARAX IM SOL 50MG/ML | 50 MG | SOLUTION | ERFA CANADA 2012 INC | CANCELLED POST MARKET | DIN 00024589 |
| HYDROXYZINE HYDROCHLORIDE INJECTION | 50 MG | LIQUID | FRESENIUS KABI CANADA LTD | CANCELLED PRE MARKET | DIN 02242864 |
| HYDROXYZINE HYDROCHLORIDE INJECTION, USP | 50 MG | SOLUTION | STERIMAX INC | DORMANT | DIN 02231209 |
Who else supplies HYDROXYZINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. HYDROXYZINE appears in 24 registered pack listings across 8 markets, published on 7 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.